Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)

被引：0

作者：

Bergmann, L. ^{[1
]}

Donskov, F. ^{[2
]}

Motzer, R. J. ^{[3
]}

Voog, E. ^{[4
]}

Hovey, E. J. ^{[5
]}

Gruellich, C. ^{[6
]}

Nott, L. M. ^{[7
]}

Cuff, K. E. ^{[8
]}

Gil, T. ^{[9
]}

Jensen, N., V ^{[10
]}

Chevreau, C. ^{[11
]}

Negrier, S. ^{[12
]}

Depenbusch, R. ^{[13
]}

Cornelio, I ^{[14
]}

Champsaur, A. ^{[14
]}

Escudier, B. J. ^{[15
]}

Pal, S. K. ^{[16
]}

Powles, T. ^{[17
]}

Choueiri, T. K. ^{[18
]}

机构：

[1] Univ Klin Frankfurt Hosp, Frankfurt, Germany

[2] Aarhus Univ Hosp, Aarhus, Netherlands

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Ctr Jean Bernard Clin Victor Hugo, Le Mans, France

[5] Prince Wales Hosp, Sydney, NSW, Australia

[6] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany

[7] Royal Hobart Hosp, Hobart, Tas, Australia

[8] Princess Alexandra Hosp, Woolloongabba, Australia

[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[10] Odense Univ Hosp, Odense, Denmark

[11] IUCT Oncopole Inst Claudius Regaud, Toulouse, France

[12] Ctr Leon Berard, Ctr Reg Lutte Canc, Lyon, France

[13] Onkodok GmbH Dedicated Res Facil, Gutersloh, Germany

[14] Exelixis Inc, San Francisco, CA USA

[15] Gustave Roussy Canc Ctr, Villejuif, France

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Queen Mary Univ London, Barts Canc Inst, London, England

[18] Dana Farber Canc Ctr, Boston, MA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P600

引用

页码：200 / 201

页数：2

共 50 条

[41] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
Choueiri, Toni K.
Escudier, Bernard J.
Les, Thomas Pow
Cella, David
Ru, Qinhua C.
Scheffold, Christian
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).
Maia, Manuel C.
Agarwal, Neeraj
McGregor, Bradley Alexander
Vaishampayan, Ulka N.
Choueiri, Toni K.
Green, Marjorie C.
Hessel, Colin
Scheffold, Christian
Schwab, Gisela
Powles, Thomas
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[43] Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).
Agarwal, Neeraj
Vaishampayan, Ulka N.
McGregor, Bradley Alexander
Green, Marjorie C.
Mohamed, Nehal
Chang, Pei-Yun
Powles, Thomas
Pal, Sumanta K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[44] Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Meric-Bernstam, Funda
Tannir, Nizar M.
Iliopoulos, Othon
Lee, Richard J.
Telli, Melinda L.
Fan, Alice C.
DeMichele, Angela
Haas, Naomi B.
Patel, Manish R.
Harding, James J.
Voss, Martin H.
Owonikoko, Taofeek K.
Carthon, Bradley
Srinivasan, Ramaprasad
Bendell, Johanna C.
Jenkins, Yonchu
Whiting, Sam H.
Orford, Keith
Bennett, Mark K.
Bauer, Todd M.
CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1540 - 1548
[45] Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Escudier, Bernard
Powles, Thomas
Motzer, Robert J.
Olencki, Thomas
Aren Frontera, Osvaldo
Oudard, Stephane
Rolland, Frederic
Tomczak, Piotr
Castellano, Daniel
Appleman, Leonard J.
Drabkin, Harry
Vaena, Daniel
Milwee, Steven
Youkstetter, Jillian
Lougheed, Julie C.
Bracarda, Sergio
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 765 - +
[46] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Grunwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Mendez Vidal, Maria Jose
Hong, Sung-Hoo
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Merchan, Jaime R.
Smith, Alan D.
Mody, Kalgi
Perini, Rodolfo F.
Xing Dongyuan
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[47] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
Rimassa, Lorenza
Cicin, Irfan
Blanc, Jean-Frederic
Klumpen, Heinz Josef
Zagonel, Vittorina
Tran, Albert
Kim, Stefano Chong Hun
Lin, Zhong-Zhe
Tam, Vincent C.
Hazra, Saswati
Mangeshkar, Milan
El-Khoueiry, Anthony
Cheng, Ann-Lii
Meyer, Tim
Kelley, Robin Kate
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[48] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
Venerito, M.
Rimassa, L.
Cicin, I
Blanc, J-F
Kluempen, H-J
Zagonel, V
Tran, A.
Kim, S.
Lin, Z-Z
Tam, V. C.
Hazra, S.
Mangeshkar, M.
El-Khoueiry, A. B.
Cheng, A-L
Meyer, T.
Kelley, R. K.
Abou-Alfa, G. K.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 283
[49] AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Hart, L. A.
Carlson, J. J.
VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
[50] Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.
Lacy, Steven
Hutmacher, Matthew M.
Yang, Bei
Motzer, Robert J.
Escudier, Bernard J.
Powles, Thomas
Choueiri, Toni K.
Miles, Dale
Nielsen, Jace
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →